Definitions

1. Clinical pharmacology is the study of pharmacodynamics and pharmacokinetics in human beings.
2. Clinical pharmacology is the study of pharmacology in relation to clinical science.
3. Clinical pharmacology is the medical field of pharmacology; it mainly concerns poisoning and complex problems of medication.
4. Clinical pharmacology is concerned with how systems of therapeutics interact with patients.
5. Clinical pharmacology is only one of its branches.

Action

1. Clinical Pharmacology Mechanism Of Action The precise mechanism(s) by which zonisamide exerts its antiseizure effect is unknown.

Humans

1. The clinical pharmacology of the antagonist has not been studied in humans.

Sleep

1. There is evidence to support the ability of ProSom to enhance the duration and quality of sleep for intervals up to 12 weeks (see CLINICAL PHARMACOLOGY).

Basic

1. The determination of a drug's dose-response curve(s) is fundamental to basic and clinical pharmacology.

Information

1. The information below, describing the clinical pharmacology of cyanocobalamin, has been derived from studies with injectable vitamin B 12.

Review

1. A review is divided into sections on medical analysis, chemistry, clinical pharmacology, biopharmaceutics, pharmacology, statistics, and microbiology.
2. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology.

Policosanol

1. Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent.

Antiepileptic Drugs

1. The clinical pharmacology of the new antiepileptic drugs.

Adults

1. Additionally, a higher rate of clearance of infliximab was observed than had been observed in adults (see CLINICAL PHARMACOLOGY, Pharmacokinetics).

Pediatric Patients

1. Furthermore, exposure in pediatric patients given 30 mg fexofenadine hydrochloride is comparable to adults given 60 mg (see CLINICAL PHARMACOLOGY).

Clinical Studies

1. The incidence of VOD reported in the literature from the randomized, controlled trials (see CLINICAL PHARMACOLOGY, CLINICAL STUDIES) was 7.7%-12%.

Preclinical

1. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor.

Clinical Medicine

1. Clinical pharmacology integrates pharmacology, pathophysiology and clinical medicine.

Additional Details

1. Additional details of these drug interaction studies are provided in the Clinical Pharmacology subsection [see CLINICAL PHARMACOLOGY].

Elderly

1. The plasma levels of oxymorphone are about 40% higher in elderly (≥65 years of age) than in younger subjects (see CLINICAL PHARMACOLOGY).
2. Single dose pharmacokinetic parameters are similar in elderly and young healthy volunteers (see CLINICAL PHARMACOLOGY, Special Populations subsection).

Geriatric

1. There were no significant differences in glimepiride pharmacokinetics between the two age groups (see CLINICAL PHARMACOLOGY, Special Populations, Geriatric).
2. With repeated administration of cinoxacin, no accumulation of drug was found in the twenty patients ages 70-89 (see Geriatric under Clinical Pharmacology).

Pharmacodynamics

1. Hydrochlorothiazide has been shown to have an additive effect (see CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects, Hypertension).

Estazolam

1. There is evidence to support the ability of estazolam to enhance the duration and quality of sleep for intervals up to 12 weeks (see CLINICAL PHARMACOLOGY).
2. Smokers have an increased clearance of benzodiazepines as compared to nonsmokers; this was seen in studies with estazolam (see CLINICAL PHARMACOLOGY).

Pharmacokinetic Studies

1. In addition, pharmacokinetic studies in children (see CLINICAL PHARMACOLOGY) have established a dose proportionality between children and adults.

Imitrex Nasal Spray

1. Therefore, the use of IMITREX Nasal Spray in patients receiving MAO-A inhibitors is contraindicated (see CLINICAL PHARMACOLOGY and CONTRAINDICATIONS).

Treatment

1. Cimetidine treatment should be stopped during treatment with ELLENCE (see CLINICAL PHARMACOLOGY).

Efficacy

1. The efficacy of ZYPREXA was established in short-term (6-week) controlled trials of schizophrenic inpatients (see CLINICAL PHARMACOLOGY).
2. Monitoring of blood levels (see CLINICAL PHARMACOLOGY) has increased the efficacy and safety of anticonvulsants.

Imitrex Tablets

1. Therefore, the use of IMITREX Tablets in patients receiving MAO-A inhibitors is contraindicated (see CLINICAL PHARMACOLOGY and CONTRAINDICATIONS).

Studies

1. Clinical pharmacology studies have confirmed this site of action in humans, and effects in other segments of the nephron have not been demonstrated.
2. In clinical pharmacology studies, there were no clinically relevant effects of age on the pharmacokinetics of cerivastatin sodium.
3. Toxicological and pharmacokinetic studies were adapted to the progress of studies in clinical pharmacology and clinical trails.

Study

1. The results of this study were published in the peer-reviewed British Journal of Clinical Pharmacology in 1989.

Journal

1. Hindmarch I, "The effects of an ergot alkaloid derivative on aspects of psychomotor performance" The journal of clinical pharmacology (1979) 726- 731.

Severe Hepatic Impairment

1. BYSTOLIC has not been studied in patients with severe hepatic impairment and therefore it is not recommended in that population [see CLINICAL PHARMACOLOGY].

Dose

1. A dose of 30 mg once daily is recommended as the starting dose in pediatric patients with decreased renal function (see CLINICAL PHARMACOLOGY).

Zonisamide

1. Zonisamide has a long half-life (see CLINICAL PHARMACOLOGY). Due to the low protein binding of zonisamide (40%), renal dialysis may not be effective.
2. Clinical pharmacology and mechanism of action of zonisamide.
3. Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide.

Dosage

1. Dose modification is recommended for patients who are also receiving a potent CYP 3A4 inducer (see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY).
2. BYSTOLIC has not been studied in patients receiving dialysis [see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION].

Special Populations

1. Single dose pharmacokinetic parameters are similar in elderly and young healthy volunteers (see CLINICAL PHARMACOLOGY, Special Populations).
2. BYSTOLIC has not been studied in patients receiving dialysis (see CLINICAL PHARMACOLOGY, Special Populations).
3. Concomitant liver disease is known to decrease the clearance of diazepam (see CLINICAL PHARMACOLOGY, Special Populations, Hepatic Impairment).

Precautions

1. A higher incidence of bleeding has been reported in patients over 60 years of age, especially women (see CLINICAL PHARMACOLOGY and PRECAUTIONS, General).

Midazolam

1. Gross tests of recovery from the effects of midazolam (see CLINICAL PHARMACOLOGY) cannot be relied upon to predict reaction time under stress.

Renal Impairment

1. Patients with renal impairment may have longer elimination half-lives for midazolam (see CLINICAL PHARMACOLOGY, Special Populations: Renal Failure).
2. Based on the pharmacokinetic results, there is no need for dosage adjustment in patients with renal impairment (see CLINICAL PHARMACOLOGY).

Patients

1. Use caution in adjusting the dose of ZEBETA in patients with renal or hepatic impairment (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).
2. BYSTOLIC has not been studied in patients with severe hepatic impairment [see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION].
3. Clinical studies indicate that lower doses of heparin may be indicated in these patients (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).

Coadministration

1. Coadministration of cisapride is contraindicated in patients receiving fluconazole (see CLINICAL PHARMACOLOGY, Drug Interaction Studies and PRECAUTIONS).

Lamotrigine

1. Hepatic metabolism to the glucuronide followed by renal excretion is the principal route of elimination of lamotrigine (see CLINICAL PHARMACOLOGY).
2. Some estrogen-containing oral contraceptives have been shown to decrease serum concentrations of lamotrigine [see Clinical Pharmacology (12.3)].

Lamictal

1. Dosing of LAMICTAL should be based on therapeutic response [see CLINICAL PHARMACOLOGY].

Drug Interactions

1. In particular, the introduction of valproate requires reduction in the dose of LAMICTAL (see CLINICAL PHARMACOLOGY: Drug Interactions).
2. Includes clinical pharmacology, indications and dosage, side effects and drug interactions, and contraindications.
3. Other drugs which have similar effects include estrogen-containing oral contraceptives [see Drug Interactions (7), Clinical Pharmacology (12.3)].

Contraindications

1. OPANA ER is contraindicated in patients with moderate and severe hepatic dysfunction (see CLINICAL PHARMACOLOGY, CONTRAINDICATIONS and PRECAUTIONS).
2. Accordingly, the coadministration of IMITREX Tablets and an MAO-A inhibitor is contraindicated (see CLINICAL PHARMACOLOGY and CONTRAINDICATIONS).
3. Accordingly, the coadministration of IMITREX Nasal Spray and an MAO-A inhibitor is contraindicated (see CLINICAL PHARMACOLOGY and CONTRAINDICATIONS).

Pharmacokinetics

1. The half-life of lamotrigine is affected by other concomitant medications (see CLINICAL PHARMACOLOGY: Pharmacokinetics and Drug Metabolism).
2. Information regarding experience in patients with hepatic dysfunction is provided in CLINICAL PHARMACOLOGY, Pharmacokinetics In Special Populations.
3. The major route of elimination of epirubicin is the hepatobiliary system (see CLINICAL PHARMACOLOGY, Pharmacokinetics in Special Populations).

Pharmacology

1. Studies can include theoretical pharmacology, in contrast to Clinical pharmacology, - the medical field of pharmacology.
2. Martin Michel, leading expert in clinical pharmacology, Head of the Department of Pharmacology and Pharmacotherapy, University of Amsterdam, Netherlands.
3. Clinical pharmacology is the medical field of pharmacology.

Therapeutic

1. Perucca 2001 Perucca E. Clinical pharmacology and therapeutic use of the new antiepileptic drugs.
2. A review of their clinical pharmacology and therapeutic applications.

Therapeutics

1. More specifically, the book should be considered by those involved in all aspects of clinical pharmacology and therapeutics.
2. This research was published online in the journal Clinical Pharmacology & Therapeutics.

Clinical Pharmacology

1. A dose of 60 mg once daily is recommended as the starting dose in patients with decreased renal function (see CLINICAL PHARMACOLOGY).
2. The half-life of LAMICTAL is affected by other concomitant medications (see CLINICAL PHARMACOLOGY: Pharmacokinetics and Drug Metabolism).
3. OPANA ER is contraindicated in patients with moderate and severe hepatic impairment (see CLINICAL PHARMACOLOGY, PRECAUTIONS and DOSAGE AND ADMINISTRATION).

Categories

1. Therapeutics
2. Nature > Chemistry > Biochemistry > Pharmacology
3. Contraindications
4. Humans > Medicine > Drugs > Drug Interactions
5. Chemistry > Biochemistry > Pharmacology > Pharmacokinetics
6. Books about "Clinical Pharmacology" in Amazon.com
   

Continue: More Keywords - - - - - - - - - -